Skip to content


Orgovyx, Ryeqo (relugolix) is a small molecule pharmaceutical. Relugolix was first approved as Orgovyx on 2020-12-18. It has been approved in Europe to treat leiomyoma. It is known to target gonadotropin-releasing hormone receptor. Orgovyx's patents are valid until 2037-09-29 (FDA).
Trade Name Ryeqo
Common Name Relugolix
Indication leiomyoma
Drug Class Gnrh receptor antagonists (nonpeptide)
Get full access now